Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.